The FDA has approved fremanezumab (marketed as Ajovy) to prevent migraine in adults. The injectable drug, given monthly or quarterly, is a humanized monoclonal antibody that targets calcitonin gene-related peptide.
In phase III trials among adults with disabling migraine, fremanezumab reduced the number of monthly migraine days over 12 weeks relative to placebo. It was given as a stand-alone treatment or in combination with oral preventives. Injection-site reactions were the most common adverse events.
Fremanezumab injections can be given by a clinician or by the patient at home.